
GPCR Stock Forecast & Price Target
GPCR Analyst Ratings
Bulls say
Structure Therapeutics is supported by compelling clinical evidence that aleniglipron delivered durable weight loss through 72 weeks, reaching up to 16.2% with no plateau, while also showing improved tolerability from lower-dose initiation and favorable liver safety with no DILI or Hy’s Law events. The company’s Phase 3 ACCOMPLISH program, enrolling up to 3,600 patients in obesity and up to 1,100 in obesity/T2D, adds a major de-risking catalyst, and management expects >$8B in worldwide peak sales potential. Beyond aleniglipron, ACCG-2671 showed target engagement, dose-proportional PK, and up to 3.3% weight loss after a single dose, broadening the pipeline and strengthening the long-term oral GPCR thesis.
Bears say
Structure Therapeutics is facing substantial clinical, commercial, and financial risk despite promising Phase 2b data for aleniglipron, because those mid-stage results still must be replicated in larger Phase 3 trials and may not hold up under broader testing. Competition is also intensifying, with several approved GLP-1 therapies and more than 20 programs in development, so aleniglipron must show a clearly differentiated efficacy and tolerability profile to win share against entrenched big pharma products. Meanwhile, the company is expected to keep incurring net losses until commercialization and likely through the early launch phase, raising the possibility of additional capital raises and uncertain dilution for shareholders.
This aggregate rating is based on analysts' research of Structure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
GPCR Analyst Forecast & Price Prediction
Start investing in GPCR
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Structure Therapeutics Inc (GPCR) Forecast
GPCR Analyst Forecast & Price Prediction
Start investing in GPCR
Order type
Buy in
Order amount
Est. shares
0 shares